Metastatic Breast Cancer
Conditions
Keywords
Aurora, breast cancer, metastatic, molecular screening, targeted gene sequencing, molecular aberrations, exploratory, biomarker
Brief summary
This program initially aims to recruit 1300 breast cancer patients from a large number of hospitals across Europe. Eligible patients are those who are 18 or older, either female or male, and who have not received more than 1 type of treatment from the time metastases were discovered, metastasi(e)s has just been diagnosed or their disease has come back (disease relapse). Biopsy samples from both the primary and metastatic (or relapsed) tumor will be collected for central analyses, together with blood, serum and plasma samples. Any samples not analyzed immediately will be stored in an independent bio-repository to enable future (not yet defined) research aimed at better understanding metastatic breast cancer. In summary, the main objectives of AURORA are to better understand the genetic aberrations in metastatic breast cancer and to discover the mechanisms of response or resistance to therapy, in order to ultimately identify the "right therapy for each individual patient". At the same time, patients with genetic aberrations that are being targeted by new drugs in development will be offered the possibility to participate in clinical trials, when approved and available in their countries. Ultimately, the aim of AURORA is to improve the outcomes of all patients diagnosed with metastatic breast cancer.
Interventions
PROCEDUREmetastatic lesion biopsy
a medical test commonly performed by a surgeon or an interventional radiologist in order to collect tissues for examination; in this case from a metastatic lesion
Sponsors
Jules Bordet Institute
Frontier Science & Technology Research Foundation, Inc.
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Female or male ≥ 18 years with diagnosis of locally recurrent/advanced BC not amenable to treatment with curative intent or MBC who have not received more than 1 line of systemic therapy (any type) in the metastatic setting. Under protocol 4.0, eligible patients will be limited to locally recurrent/advanced breast cancer not amenable to treatment with curative intent or MBC with: * histopathology-confirmed TNBC as defined by ER \<1% and HER2 negative following ASCO-CAP guidelines * ILC (either based on ILC morphology or negative E-cadherin expression confirmed by IHC). Mixed ILC/invasive ductal carcinoma are not eligible for the ILC cohort. * late relapse BC (any subtype). Late relapse is defined as a patient with a radiologic or histologic confirmation of advanced or MBC relapse \> 10 years from the primary BC diagnosis. 2. Written informed consent prior to registration into the program. 3. Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1. 4. Availability of primary tumor tissue for research purposes. 5. Patient must have a metastatic lesion accessible for biopsy and must agree with the biopsy procedure. 1. Up until protocol 3.0, up to 100 patients with bone-only metastasis have been included without a metastatic biopsy, if plasma samples have been collected at screening, and if the patient met all other eligibility criteria. 2. In protocol 4.0, metastatic tumor biopsies from bone lesions will be accepted provided that the chosen site of biopsy was not previously irradiated. 3. Brain tissue is accepted if it is obtained through surgical excision not planned for AURORA, but as part of the routine clinical practice. 6. The biopsy of the metastatic lesion must be conducted either at the initial diagnosis of the BC relapse before the initiation of 1st line systemic therapy or at the 1st disease progression before initiation of a second line systemic treatment. There is no restriction in the type of therapeutic modality considered as 1st line systemic treatment, which can consist of any type of treatment administered after the diagnosis of the advanced BC relapse till the 1st disease progression thereafter. 7. Biopsies obtained during routine clinical practice are accepted if both formalin-fixed paraffin-embedded (FFPE) and Frozen Tissue (FT) blocks were collected concurrently from the same metastatic lesion and if collected at the pre-specified timelines for AURORA. 8. Availability of a whole blood, serum and plasma samples collected at the time of screening. 9. Patient agrees to provide blood samples at regular intervals, from the screening as well as during the follow-up phase of the program.
Exclusion criteria
1. The patient has received more than 1 line of systemic therapy (any type) in the metastatic setting. 2. Patients who have received prior palliative radiotherapy to the only site that is accessible to biopsy. 3. Presence of severe hematopoietic, renal, and/or hepatic dysfunction, including but not restricted to albumin \< 3 g/dl. 4. Known increased risk of hemorrhage during biopsy procedure, as evaluated by the treating physician. 5. Previous or current malignancies of other histologies within the last 5 years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Metastatic Breast Cancer (MBC) understanding | 1 year after end of acrrual | To improve the understanding of locally recurrent/advanced BC and MBC by using high-throughput technologies on primary, metastatic, as well as plasma ctDNA samples, to explore tumor heterogeneity, clonal evolution and transcriptional changes associated with mutational and copy number variation (CNV) patterns. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Identification of "exceptional responders" and "rapid progressors"; the outlier patients | 1 year after end of accrual and subsequently during follow up period of 10 years | To discover biomarkers of response and/or resistance to systemic therapy using genomic and transcriptomic data of "exceptional responders" and "rapid progressors" (collectively referred to as "outliers", as defined in the AURORA protocol). |
| Feasibility of implementing a global molecular screening platform for MBC | 1 year after end of accrual | To provide evidence that can contribute in assessing the feasibility of implementing a global molecular screening platform of MBC |
| Patient identification to match with biomarker-driven clinical trials | on ongoing basis during 3 years' patient recruitment | To identify patients with candidate driver alterations in their tumors that can be matched to biomarker-driven clinical trials. |
| Building new therapeutic hypotheses | 1 year after end of accrual and subsequently during follow up period of 10 years | To build new therapeutic hypotheses based on findings generated by Targeted Gene Sequencing (TGS). |
| Patients' prognosis determination | 1 year after end of accrual and subsequently during follow up period of 10 years | To evaluate the prognostic relevance of genomic alterations detected in plasma ctDNA samples, tumor metastatic biopsies and archived primary tissue. |
| Correlation between molecular alterations and standardly assessed efficacy endpoints | 1 year after end of accrual and subsequently during follow up period of 10 years | To correlate molecular alterations in patients with the efficacy endpoints (response rate, progression-free survival and overall survival). |
Countries
Belgium, Germany, Iceland, Italy, Luxembourg, Portugal, Spain, Sweden, Switzerland, United Kingdom
Contacts
CONTACTAURORA BIG HQ
PRINCIPAL_INVESTIGATORPhilippe Aftimos, MD
Institut Jules Bordet, Brussels, Belgium
PRINCIPAL_INVESTIGATORAngel Guerrero Zotano, MD
Instituto Valenciano de Oncologia, Valencia, Spain
PRINCIPAL_INVESTIGATORMatteo Benelli, PhD
Breast International Group
Outcome results
None listed